Gilead partners with WuXi for R&D; Isis advances a Bayer-partnered drug;

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> Gilead Sciences ($GILD) is working with Chinese CRO WuXi PharmaTech ($WX), tasking the company with handling analytical and stability studies of investigational drugs to support global marketing applications. News

> Isis Pharmaceuticals ($ISIS) launched a Phase II study on its Bayer-partnered treatment for clotting disorders, putting it in line for a $55 million milestone payment. More

> The potential merger of Pfizer ($PFE) and Allergan ($ACT) has stirred up fresh critiques of U.S. tax policy from presidential candidates Hillary Clinton and Donald Trump. Story

Medical Device News

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Quest Medical launches recall for open heart surgery drug delivery devices. Story

> Sanofi recalls epinephrine injector devices from U.S. and Canada. Article

> Zimmer Biomet raises guidance as it squeezes out more synergies, but whence growth? More

Pharma News

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report

> Patent challenger Bass wins IP reviews for Celgene, Shire meds. Article

> Mylan beats Street's estimates with Q3 earnings and beats Perrigo in effort to derail tender. Item

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.